

(12) **UK Patent Application** (19) **GB** (11) **2 235 627** (13) **A**  
(43) Date of A publication 13.03.1991

(21) Application No 9019659.3

(22) Date of filing 07.09.1990

(30) Priority data

(31) 8920392  
8923644

(32) 08.09.1989  
20.10.1989

(33) GB

(71) Applicant

**Glaxo Group Limited**

**(Incorporated in the United Kingdom)**

**Clarges House, 6-12 Clarges Street, London,  
W1Y 8DH, United Kingdom**

(72) Inventor

**James Barry Douglas Palmer**

(74) Agent and/or Address for Service

**Frank B Dehn & Co  
Imperial House, 15-19 Kingsway, London, WC2B 6UZ,  
United Kingdom**

(51) INT CL<sup>6</sup>

**A61K 9/72 31/56 // (A61K 31/56 31:065)**

(52) UK CL (Edition K)

**A5B BX B24Y B240 B241 B245 B246 B247 B42Y  
B422 B43Y B431 B48Y B482 B58Y B586 B64Y  
B646 B822 B823 B841  
U1S S2416**

(56) Documents cited

**None**

(58) Field of search

**UK CL (Edition K) A5B BJA BX  
INT CL<sup>6</sup> A61K  
Online databases: CHABS; DIALOG ONESEARCH-  
PATENTS, MEDICINE**

(54) **Inhalation medicaments**

(57) Pharmaceutical compositions comprising effective amounts of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.

**GB 2 235 627 A**

54-659.520

MEDICAMENTS

5 This invention relates to improvements in the  
treatment of asthma and other respiratory disorders.  
More particularly, it relates to the use of a  
bronchodilator drug in combination with a steroidal  
anti-inflammatory drug for the treatment of respiratory  
disorders such as asthma, and to pharmaceutical  
10 compositions containing the two active ingredients.

Asthma is a condition characterised by variable,  
reversible obstruction of the airways which is caused by  
a complex inflammatory process within the lungs. In  
most cases, this process is initiated and maintained by  
15 the inhalation of antigens by sensitive atopic  
individuals (extrinsic asthma). However, in some  
patients it is caused by other mechanisms which at  
present are poorly understood but do not involve an  
allergic process (intrinsic asthma). The disease has  
20 therefore two components, spasm of the bronchial (or  
breathing) tubes and inflammation or swelling of the  
breathing tubes.

Salbutamol, the first highly selective  $\beta_2$ -  
adrenoceptor stimulant has been used successfully and  
25 effectively by inhalation for the immediate relief of  
spasm in asthma. However, when given by inhalation,  
salbutamol has usually a four to six hour duration of  
action, which is too short either to control nocturnal  
asthma or for convenient maintenance of the disease in  
30 some patients.

Anti-inflammatory corticosteroids such as, for  
example, beclomethasone dipropionate have also been  
administered by inhalation in the treatment of asthma,  
although unlike salbutamol the therapeutic benefits  
35 resulting from reduced inflammation may not be  
immediately apparent.

It has been recognised that asthma may be treated by using both a bronchodilator for immediate relief and a prophylactic anti-inflammatory corticosteroid to treat the underlying inflammation. Such combination therapy directed at the two main underlying events in the lung (i.e. relief of spasm in the breathing tubes and treatment of inflammation in the breathing tubes) using a combination of salbutamol and beclomethasone dipropionate has previously been proposed (Ventide, Glaxo Group trade mark), but suffers a number of disadvantages in view of the above-mentioned short duration of action exhibited by salbutamol. Thus the need for a 4-hourly dosing regimen may discourage effective patient compliance and also renders the product less than satisfactory in the treatment of nocturnal asthma since the bronchodilator may not remain effective for the duration of the night, leading to impaired sleep for asthmatics troubled by nocturnal cough, breathlessness and wheeze.

The present invention is based on the concept of a novel combination therapy which has markedly greater efficiency and duration of bronchodilator action than previously known combinations and which permits the establishment of a twice daily (bis in diem - b.i.d) dosing regimen with consequent substantial benefits in, for example, the treatment of asthma, particularly nocturnal asthma.

Thus we have found that if the  $\beta_2$ -adrenoreceptor stimulant bronchodilator salmeterol and/or a physiologically acceptable salt thereof is combined with the anti-inflammatory corticosteroid fluticasone propionate in a form suitable for administration by inhalation, the resulting compositions may be administered on a b.i.d. basis to provide highly effective treatment and/or prophylactic therapy for asthmatics. In particular such administration has been shown to lead to significant improvement in daytime lung

function, requirement for additional symptomatic bronchodilator and almost complete abolition of nocturnal asthma while giving rise to minimal systemic side effects.

- 5           Salmeterol is one of a range of bronchodilators having extended duration of action which is described in British Patent Specification No. 2140800, and is systematically named 4-hydroxy- $\alpha^1$ -[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol.
- 10       Fluticasone propionate is one of a range of topical anti-inflammatory corticosteroids with minimal liability to undesired systemic side effects which is described in British Patent Specification No. 2088877, and is systematically named S-fluoromethyl 6 $\alpha$ ,9 $\alpha$ -difluoro-11 $\beta$ -
- 15       hydroxy-16 $\alpha$ -methyl-17 $\alpha$ -propionyloxy-3-oxoandrosta-1,4-diene-17 $\beta$ -carbothioate. We have found these two compounds to be particularly compatible and complementary in their activity and thus highly effective in the treatment of asthma and other
- 20       respiratory disorders.

          Thus according to one aspect of the invention there are provided pharmaceutical compositions comprising effective amounts of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone

25       propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.

          The invention additionally relates to the use of salmeterol (and/or a physiologically acceptable salt

30       thereof) and fluticasone propionate in the manufacture of pharmaceutical compositions as combined preparations for simultaneous, sequential or separate administration of salmeterol and fluticasone propionate by inhalation in the treatment of respiratory disorders.

35       According to a further feature of the invention there is provided a method of treating respiratory disorders which comprises the simultaneous, sequential

or separate administration by inhalation of effective amounts of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate.

Suitable physiologically acceptable salts of salmeterol include acid addition salts derived from inorganic and organic acids, such as the hydrochloride, hydrobromide, sulphate, phosphate, maleate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, salicylate, acetate, fumarate, succinate, lactate, glutarate, gluconate, tricarballlylate, hydroxynaphthalenecarboxylate e.g. 1-hydroxy- or 3-hydroxy-2-naphthalenecarboxylate, or oleate. Salmeterol is preferably used in the form of its 1-hydroxy-2-naphthalene carboxylate salt (hydroxynaphthoate).

For administration by inhalation, the compositions according to the invention are conveniently delivered by conventional means, e.g. in the form of a metered dose inhaler prepared in a conventional manner or in combination with a spacer device such as the Volumatic (Glaxo Group trade mark) device. In the case of a metered dose inhaler, a metering valve is provided to deliver a metered amount of the composition. Spray compositions may for example be formulated as aqueous solutions or suspensions and may be administered by a nebuliser. Aerosol spray formulations, for example in which the active ingredients are suspended, optionally together with one or more stabilisers, in a propellant, e.g. a halogenated hydrocarbon such as trichlorofluoromethane, dichlorodifluoromethane, 1,2-dichlorotetrafluoroethane, trichlorotrifluoroethane, monochloropentafluoroethane, chloroform or methylene chloride, may also be employed. The two drugs may be administered separately in similar ways.

Alternatively, for administration by inhalation or insufflation, the compositions according to the

invention may take the form of a dry powder composition, for example a powder mix of the active ingredients and a suitable carrier such as lactose. The powder compositions may be presented in unit dosage form in, for example, capsules, cartridges or blister packs from which the powder may be administered with the aid of an inhaler such as the Rotahaler inhaler (Glaxo Group trade mark) or in the case of blister packs by means of the Diskhaler inhaler (Glaxo Group trade mark).

10       The ratio of salmeterol to fluticasone propionate in the compositions according to the invention is preferably within the range 4:1 to 1:20. The two drugs may be administered separately in the same ratio. Each metered dose or actuation of the inhaler will generally  
15       contain from 25  $\mu\text{g}$  to 100  $\mu\text{g}$  of salmeterol and from 25  $\mu\text{g}$  to 500  $\mu\text{g}$  of fluticasone propionate. As hereinbefore indicated, it is intended that the pharmaceutical compositions will be administered twice daily.

20       A suitable daily dose of salmeterol for inhalation is in the range 50  $\mu\text{g}$  to 200  $\mu\text{g}$ .

      A suitable daily dose of fluticasone propionate for inhalation is in the range 50  $\mu\text{g}$  to 2000  $\mu\text{g}$  depending on the severity of the disease.

25       The precise dose employed will of course depend on the method of administration, the age, weight and condition of the patient and will be determined by the clinician depending on the severity and the type of asthma.

30       In order that the invention may be more fully understood, the following examples are given by way of illustration only.

EXAMPLE 1 - Metered Dose Inhaler

	<u>Active Ingredient</u>	<u>Target per Actuation</u>	<u>Per Inhaler % w/w</u>
5			
	Salmeterol (as hydroxynaphthoate)	25.0 µg	0.0448
10	Fluticasone propionate	25.0 µg	0.0309
	Stabiliser	5.0 µg	0.0076
	Trichlorofluoromethane	23.70 mg	27.8759
15	Dichlorodifluoromethane	61.25 mg	72.0588

20 EXAMPLE 2 - Metered Dose Inhaler

	<u>Active Ingredient</u>	<u>Target per Actuation</u>	<u>Per Inhaler % w/w</u>
25	Salmeterol (as hydroxynaphthoate)	25.0 µg	0.0448
	Fluticasone propionate	50.0 µg	0.0618
30	Stabiliser	7.5 µg	0.0106
	Trichlorofluoromethane	23.67 mg	27.8240
	Dichlorodifluoromethane	61.25 mg	72.0588
35			

EXAMPLE 3 - Metered Dose Inhaler

	<u>Active Ingredient</u>	<u>Target per Actuation</u>	<u>Per Inhaler % w/w</u>
5	Salmeterol (as hydroxynaphthoate)	25.0 µg	0.0448
	Fluticasone propionate	250.0 µg	0.3088
10	Stabiliser	25.0 µg	0.0309
	Trichlorofluoromethane	23.45 mg	27.5567
15	Dichlorodifluoromethane	61.25 mg	72.0588

EXAMPLE 4 - Metered Dose Inhaler

20	<u>Active Ingredient</u>	<u>Target per Actuation</u>	<u>Per Inhaler % w/w</u>
	Salmeterol (as hydroxynaphthoate)	25.0 µg	0.0448
25	Fluticasone propionate	125.0 µg	0.1544
	Stabiliser	15.0 µg	0.0175
30	Trichlorofluoromethane	23.56 mg	27.7244
	Dichlorodifluoromethane	61.25 mg	72.0588
35			



EXAMPLE 5 - Metered Dose Inhaler

	<u>Active Ingredient</u>	<u>Target per</u> <u>Actuation</u>	<u>Per Inhaler</u> <u>% w/w</u>
5	Salmeterol (as hydroxynaphthoate)	100.0 µg	0.1791
	Fluticasone propionate	250.0 µg	0.3088
10	Stabiliser	25.0 µg	0.0309
	Trichlorofluoromethane	23.43mg	27.4224
15	Dichlorodifluoromethane	61.25 mg	72.0588

In Examples 1 to 5 micronised fluticasone propionate and micronised salmeterol (as the hydroxynaphthoate) are added in the proportions given above either dry or after predispersal in a small quantity of stabiliser (disodium dioctylsulphosuccinate, lecithin, oleic acid or sorbitan trioleate)/trichlorofluoromethane solution to a suspension vessel containing the main bulk of the trichlorofluoromethane solution. The resulting suspension is further dispersed by an appropriate mixing system using, for example, a high shear blender, ultrasonics or a microfluidiser until an ultrafine dispersion is created. The suspension is then continuously recirculated to suitable filling equipment designed for cold fill or pressure filling of dichlorodifluoromethane. Alternatively, the suspension may be prepared in a suitable chilled solution of stabiliser, in trichlorofluoromethane/  
dichlorodifluoromethane.

EXAMPLE 6 - Metered Dose Dry Powder Formulation

	<u>Active Ingredient</u>		<u>µg/cartridge or blister</u>
5	Salmeterol (as hydroxynaphthoate)		36.3
	Fluticasone propionate		50.00
10	Lactose Ph.Eur.	to	12.5 mg or
		to	25.0mg

15      EXAMPLE 7 - Metered Dose Dry Powder Formulation

	<u>Active Ingredient</u>		<u>µg/cartridge or blister</u>
20	Salmeterol (as hydroxynaphthoate)		72.5
	Fluticasone propionate		50.00
25	Lactose Ph.Eur.	to	12.5 mg or
		to	25.0 mg

EXAMPLE 8 - Metered Dose Dry Powder Formulation

	<u>Active Ingredient</u>	<u>µg/cartridge or blister</u>
5	Salmeterol (as hydroxynaphthoate)	72.5
	Fluticasone propionate	100.00
10	Lactose Ph.Eur.	to 12.5 mg or to 25.0 mg

15 EXAMPLE 9 - Metered Dose Dry Powder Formulation

	<u>Active Ingredient</u>	<u>ug/cartridge or blister</u>
20	Salmeterol (as hydroxynaphthoate)	72.5
	Fluticasone propionate	250
25	Lactose Ph.Eur.	to 12.5 mg or to 25.0 mg

EXAMPLE 10 - Metered Dose Dry Powder Formulation

5	<u>Active Ingredient</u>	<u>µg/cartridge or blister</u>
	Salmeterol (as hydroxynaphthoate)	72.5
10	Fluticasone propionate	500.0
	Lactose Ph. Eur.	to 12.5 mg or to 25.0 mg

15      EXAMPLE 11 - Metered Dose Dry Powder Formulation

	<u>Active Ingredient</u>	<u>µg/cartridge or blister</u>
20	Salmeterol (as hydroxynaphthoate)	145.0
	Fluticasone propionate	250.0
25	Lactose Ph. Eur.	to 12.5 mg or to 25.0 mg

In Examples 6 to 11 the active ingredients are  
micronised and bulk blended with the lactose in the  
30 proportions given above. The blend is filled into hard  
gelatin capsules or cartridges or in specifically  
constructed double foil blister packs (Rotadisks  
blister packs, Glaxo Group trade mark) to be  
administered by an inhaler such as the Rotahaler inhaler  
35 (Glaxo Group trade mark) or in the case of the blister  
packs with the Diskhaler inhaler (Glaxo Group trade  
mark).

54-659.523

CLAIMS:

5 1. Pharmaceutical compositions comprising effective  
amounts of salmeterol (and/or a physiologically  
acceptable salt thereof) and fluticasone propionate as a  
combined preparation for simultaneous, sequential or  
separate administration by inhalation in the treatment  
10 of respiratory disorders.

2. Compositions as claimed in claim 1 wherein  
salmeterol is present as its 1-hydroxy-2-naphthoate  
salt.  
15

3. Compositions as claimed in claim 1 or claim 2  
presented as a metered spray composition or a dry powder  
composition.

20 4. Compositions as claimed in any of claims 1 to 3 in  
dosage unit form containing 25-100 $\mu$ g of salmeterol  
(optionally in the form of a physiologically acceptable  
salt thereof) and 25-500 $\mu$ g of fluticasone propionate per  
dosage unit.

25 5. The use of salmeterol (and/or a physiologically  
acceptable salt thereof) and fluticasone propionate in  
the manufacture of pharmaceutical compositions as  
combined preparations for simultaneous, sequential or  
30 separate administration of salmeterol and fluticasone  
propionate by inhalation in the treatment of respiratory  
disorders.

35 6. The use of salmeterol (and/or a physiologically  
acceptable salt thereof) and fluticasone propionate  
according to claim 5 in the manufacture of  
pharmaceutical compositions for administration on a  
twice daily basis.